ClinicalTrials.gg
Active, not recruitingNCT05254314GATA-3Updated Oct 1, 2026

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

A Phase 2 interventional study of Semaglutide Pen Injector 2.4mg weekly and Placebo in Asthma, sponsored by Vanderbilt University Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Vanderbilt University Medical Center · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Updated Oct 1, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Asthma by Vanderbilt University Medical Center — 1 open to participants now, 2 under way, none of them phase 3. Asthma · Vanderbilt University Medical Center.

Planned enrollment
6th of 13
100 · median 40
Started
2022
the only one that year
Phase 2
2 of 14
none open now
Registered
13th of 14
by date

Among the 14 studies in Asthma by Vanderbilt University Medical Center, this one is the 6th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2022, is one of 2 in phase 2, and was the 13th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 14 studies in Asthma by Vanderbilt University Medical Center is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Asthma by Vanderbilt University Medical Center, or all of them as a file.
02

Study summary

This is a randomized placebo-controlled trial of semaglutide, an FDA-approved therapy for the treatment of type 2 diabetes mellitus and obesity, in adults with symptomatic asthma despite the use of inhaled steroids and with excess body weight. This study will test the central hypothesis that semaglutide will improve asthma control and reduce airway inflammation due to direct effects on the respiratory tract in adult asthma associated with obesity.

Read the detailed description

This is a proof-of-principal randomized, double-blind, placebo-controlled, single-site clinical trial of semaglutide in adult (age 18 or older, n=100), obesity-related (BMI≥30), symptomatic asthma without type II diabetes. This study will monitor clinical asthma symptom and quality of life questionnaires and airway function to determine the effect of semaglutide on asthma control. Markers of respiratory tract and adipose tissue inflammation will be monitored to determine the effect of semaglutide on airway inflammation. Study participants will be monitored for 4 weeks before assignment to treatment with the study drug for 24 weeks followed by a 2 week final monitoring period.

03

Conditions studied

  • Asthma

Keywords

  • Asthma
  • Obesity
  • Semaglutide
  • Glucagon-like peptide-1 receptor agonist
  • www.tnasthmaobesitystudy.com
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. . Subject must be able to understand and provide .
  2. Males and females age 18 or older
  3. Obesity defined as (BMI) >=30, or >=27 in the setting of >=1 weight-related comorbidity:

    • clinically documented hypertension (>130 mmHg systolic or >85 mmHg diastolic or treatment) in the prior year or during run-in
    • clinically documented dyslipidemia (Triglycerides ш 150 mg/dl, HDL \<40 mg/dl in males or \<50 mg/dl in females, >=130 mg/dl or treatment) in the prior year or during run-in
    • current obstructive sleep apnea treatment
    • documented pre-diabetes defined by A1c 5.7-\<6.5 in the prior year or during run-in
    • clinically documented cardiovascular disease
  4. History of physician-diagnosed asthma
  5. Persistent Asthma as determined by the requirement of at least medium-dose daily inhaled or more
  6. Symptomatic asthma with an ACQ-6 score >=1.5 at enrollment and at the time of randomization
  7. Patient report of stable asthma controller regimen for the prior 8 weeks
  8. Evidence of bronchodilator responsiveness (>=12% and at least 200 mL increase in ) or airway hyperresponsiveness with a Methacholine PC20 \<=16 mg/mL or PD20 \<=400 mcg in the prior year
  9. Female subjects of must have a negative pregnancy test upon study entry
  10. Female subjects of childbearing potential must agree to use a highly effective method (e.g. hormonal, surgical or abstinence) for the duration of the study

Exclusion criteria

Exclusion Criteria:

At enrollment:

  1. Inability or unwillingness of a subject to give written or comply with the study protocol
  2. Diagnosis of type I or type II diabetes mellitus (DM) or ≥6.5 on screening labs
  3. Use of >8 puffs/inhalations of short-acting bronchodilators most days in the previous week (i.e. answer to question #6 on ACQ-6 = 4, 5, or 6)
  4. Oxygen saturation \< 94% on room air
  5. Patient-reported Tobacco, e-cigarette, or smoked marijuana use within 12 months#, or >10 pack-years of use*

    • Can still be enrolled if ≥40 years old, smoked \<20 pack years, none within 12 months#, and demonstrate a post-bronchodilator /FVC ratio of >0.7 or a DLCO z-score of -1.645 or greater (or the equivalent ≥ 75% of predicted) documented in prior 12 months or during run-in

      * Smoking equivalent pack years. One pack of cigarettes a day for 1 year is equivalent to:

    • 1 cigar or pipe per day for 1 year
    • Smoked hookah or shisha =1 session per day for 1 year
    • Vaped e-cigarettes =0.5 mLs e-liquid per day for 1 year, or =1 cartridge/tank/pod per day for 1 year
    • 1 use of inhaled marijuana per day for 1 year

      #Use of any inhalant >1 time weekly in the past year is considered use within 12 months.

    • Active smoking of conventional tobacco, inhaling of marijuana or other drugs, or vaping of e-cigarettes or vape pods >1 time per week in the past year.
    • Any form of tobacco qualifies, such as: 1 cigarette, 1 hookah or shisha sessions, 1 cigar, 1 pipe, etc.
    • Any electronic (e)-device included: e-cigarette e-cig, mod, vape pen, JUUL, e-cigar, e-hookah, e-pipe, vape pods, etc.
    • Any form of inhaled marijuana, including smoking marijuana leaves or inhaling THC via e-cigarette or device
  6. Pregnancy by urine testing, current lactation, or plans to become pregnant during the study period
  7. Pharmaceutical weight loss treatment for >7 days in the prior 90 days at enrollment
  8. Previous surgical weight loss treatment. Can still be enrolled if surgery > 5 years ago and evidence of stable or increasing weight in the prior 3-12 months.
  9. Personal history of pancreatitis as determined by history
  10. Personal or family history of medullary thyroid cancer by history or multiple endocrine neoplasia syndrome type 2
  11. Personal history of gallstone disease without previous cholecystectomy
  12. Personal history of gastroparesis
  13. Personal history of to semaglutide
  14. Personal history of hypersensitivity to local amide type (ex. Lidocaine) anesthetics
  15. Use of antidiabetic agent, other than metformin, including GLP-1R agonist in the previous 90 days. Metformin is allowed provided the dose has been stable in the 90 days prior to screening and will remain stable for the duration of the trial.
  16. Use of systemic in the past 28 days
  17. Use of monoclonal antibody for the treatment of asthma in the past 120 days
  18. Myocardial infarction, unstable angina, stroke, or heart failure ( class II) within 1 year by history
  19. Patient report and confirmed by review of historical diagnostic testing by study physician of other physician-diagnosed chronic respiratory diseases: , cystic fibrosis, pulmonary hypertension, interstitial lung disease, sarcoidosis, bronchiectasis
  20. History of physician-diagnosed immune deficiency.
  21. History of physician-diagnosed (other than excised non-melanoma skin cancer) in the past 5 years.
  22. Current uncontrolled hypertension (systolic >150, diastolic >90) or untreated hyperthyroidism
  23. Current, diagnosed or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements.
  24. Use of drugs within 20 weeks of participation, other than vaccines and/or treatments for SARS-CoV-2 authorized for emergency use
  25. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the subject's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

    At randomization:

  26. Screening creatinine elevation with EGFR\<30 ml/min/1.73 m2 collected at visit 1a
  27. Compliance to baseline asthma inhaler therapy of \<80% during run-in, at the time of randomization.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Study Drug (Semaglutide)

    Semaglutide 2.4mg once weekly

    Drug: Semaglutide Pen Injector 2.4mg weekly

  • Placebo comparator
    Placebo

    Placebo 2.4mg once weekly

    Other: Placebo

Interventions

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Once weekly subcutaneous injection

    Also known as: Wegovy

  • OtherPlacebo

    Once weekly subcutaneous injection

06

What researchers measure

Primary outcomes

  1. The efficacy of semaglutide on asthma control questionnaire-7 score in subjects with symptoms, persistent asthma and obesity.

    The primary clinical outcome is the difference between the treatment and placebo groups in change from baseline in asthma control questionnaire (ACQ)-7 score to week 12. The ACQ-7 scale ranges from 0-6 with lower scores indicating better asthma control.

    Time frame: Baseline to week 12

  2. The impact of semaglutide once weekly on serum periostin in subjects with symptomatic, persistent asthma and obesity.

    The primary mechanistic outcome is the difference between the treatment and placebo groups in change from baseline in serum periostin at week 4.

    Time frame: Baseline to week 4

Secondary outcomes

  1. The impact of semaglutide on weight loss over time.

    The change from baseline in weight to week 24.

    Time frame: Baseline to week 24

  2. The efficacy of semaglutide once weekly on asthma control questionnaire-6 score in subjects with symptomatic, persistent asthma and obesity

    The change from baseline in ACQ-6 score to week 12. The ACQ-6 scale ranges from 0-6 with lower scores indicating better asthma control.

    Time frame: Baseline to week 12

  3. The maximal dose of semaglutide tolerated in persistent asthma with obesity.

    The maximum tolerated dose of the investigational product at week 24.

    Time frame: Baseline to week 24

  4. Incidence of treatment-emergent adverse events from semaglutide in persistent asthma with obesity.

    The treatment-emergent adverse events from first dose to the completion of follow up at week 26.

    Time frame: Baseline to week 26

  5. The change in exhaled nitric oxide from semaglutide to week 12.

    The change from baseline in exhaled nitric oxide at weeks 4 and 12.

    Time frame: Baseline to week 4 and week 12

  6. The change in serum periostin from semaglutide to week 12.

    The change from baseline in serum periostin at week 12.

    Time frame: Baseline to week 4 and week 12

07

Study locations

1 site
08

References and documents

Publications

  • Tomasello A, Bacharier LB, Becker PM, Dempsey C, Wu P, Peebles RS, Niswender K, Dupont WD, Bernard G, Cahill KN. Untangling obese asthma: Design of proof-of-concept study of semaglutide in poorly controlled asthma. J Allergy Clin Immunol Glob. 2025 Dec 17;5(2):100627. doi: 10.1016/j.jacig.2025.100627. eCollection 2026 Mar. PubMed 41567689 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Sep 2026, 47 months.

Of 62 non-industry phase 2 interventional studies under Asthma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 62. This study's 47 months is close to that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2022
First posted
Feb 24, 2022
StartActual
Oct 11, 2022
Primary completionActual
Sep 28, 2026
CompletionEst.
Dec 30, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Sep 28, 2026 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Primary completion Sep 30, 2026→Sep 28, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05254314
Responsible party
Katherine Cahill, MD (Medical Director of Asthma Clinical Research, Vanderbilt University Medical Center) — Principal investigator
First posted
Feb 24, 2022
Start date
Oct 11, 2022
Primary completion
Sep 28, 2026
Completion
Dec 30, 2026 (estimated)
Last update
Oct 1, 2026

Study contacts

Katherine Cahill, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion